The current UNAIDS strategy calls for an end to HIV-related discrimination and fewer than 500,000 annual deaths from AIDS. Out of ten highlighted targets within the strategy, three center on prevention tools. Excerpted from AVAC Report 2016: Big Data, Real People.
UNAIDS 2016-2021 Strategy: What Does it Say about Prevention?
Key Population and Data Gaps
In too many countries and communities around the world key populations, including gay men and other men who have sex with men (MSM), transgender women, sex workers and people who inject drugs are subject to what Johns Hopkins researcher and advocate Stefan Baral terms “the data paradox”, meaning there “there is the least amount of data characterizing the needs of gay men and other MSM in the most stigmatizing settings.”
This graphic was excerpted from AVAC Report 2016: Big Data, Real People.
Microbicides by the Numbers: Science, products, money and more
The term “microbicide” refers to substances being studied that could be used in the vagina and/or rectum to reduce the risk of HIV infection via sexual exposure. There are no licensed microbicides available today. Simple, easy-to-use microbicides would help these individuals take control of their own health—while offering people everywhere an additional, needed option. The graphics below represent key facts about the microbicide field.
MPT Products in the Pipeline: Selected highlights
This table shows which MPTs are further along in testing for both sustained-release and on-demand products. Women will have different needs and preferences throughout their lives. An array of different types of products is key to meeting the varying needs of different women. Excerpted from the MPTs factsheet.
Vaccines Clinical Trials Snapshot
Excerpted from our quick, colorful and comprehensive vaccines research four-pager, the centerspread tracks the current status and future possibilities of all potential vaccines approaches being test. The centerspread also has a list of what advocates’ should be on the lookout for.
bNAb Targets on HIV
Scientists have mapped the shape and structure of bNAbs and identified points of contact and binding with the envelope trimer, shown in this graphic. Understanding the shape of the binding sites for bNAbs is key to vaccine development.
The Number of Vaccines Trials (2016)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Number of Broadly Neutralizing Antibodies Discovered
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Vaccines Clinical Trial Participants by Region
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
New HIV Infections by Region (2014)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.